Guardian Pharmacy Services, Inc. SEC Filings

Cardinal Equity Fund, L.P., a member of the 10% owner group of Guardian Pharmacy Services, Inc., reported an open-market sale of 275,728 shares of Class A common stock on March 20, 2026 at an average price of $29.6825 per share.

The shares were sold pursuant to an underwriting agreement among the company, certain selling stockholders, and underwriters led by BofA Securities and Jefferies. Following this transaction, Cardinal Equity Fund directly holds 345,123 shares of Guardian Pharmacy Class A common stock.

Guardian Pharmacy Services director and 10% owner Thomas J. Salentine Jr. reported a large stock sale executed by an affiliated entity. Bindley Capital Partners I, LLC, an entity associated with him, sold 3,570,677 shares of Class A Common Stock on March 20, 2026 at an average price of $29.6825 per share in an underwritten offering led by BofA Securities and Jefferies. Following the transaction, the filing shows 4,469,316 shares held indirectly through Bindley Capital Partners I, LLC and 35,714 shares held directly in his name.

Bindley Capital Partners I, LLC, a 10% owner of Guardian Pharmacy Services, Inc., reported selling 3,570,677 shares of Class A common stock at an average price of $29.6825 per share on March 20, 2026. The sale was made as part of an underwritten offering pursuant to an underwriting agreement with BofA Securities and Jefferies. After this transaction, Bindley Capital Partners I, LLC continues to hold 4,469,316 shares of Guardian Pharmacy Services Class A common stock.

Guardian Pharmacy Services director-related entities sold shares in an underwritten offering. On March 20, 2026, Pharmacy Investors, LLC sold 827,636 shares of Class A common stock at $29.6825 per share, while Cardinal Equity Fund, L.P. sold 275,728 shares at the same price.

Both transactions are indirect holdings associated with director John Ackerman and were executed as open-market sales pursuant to an underwriting agreement with BofA Securities and Jefferies as representatives of the underwriters. After these sales, Pharmacy Investors, LLC still held 1,035,928 shares and Cardinal Equity Fund, L.P. held 345,123 shares.

Guardian Pharmacy Services, Inc. director and 10% owner William E. Bindley reported an indirect open‑market sale of 3,570,677 shares of Class A common stock at an average price of $29.6825 per share. The shares were held by Bindley Capital Partners I, LLC and were sold pursuant to an underwriting agreement with BofA Securities, Inc. and Jefferies LLC. Following this secondary sale, Bindley Capital Partners I, LLC continues to hold 4,469,316 shares of Class A common stock indirectly associated with Bindley.

Guardian Pharmacy Services, Inc. completed a non-dilutive “synthetic secondary” share offering and shifted its NYSE governance status. The company sold 1,020,000 new Class A shares at a public price of $31.00 per share (less a $1.3175 underwriting discount) as part of a 6,900,000-share underwritten offering, alongside 5,880,000 shares sold by existing holders.

Guardian used all proceeds from its 1,020,000 newly issued shares to repurchase and cancel 1,020,000 outstanding Class A shares from certain holders under stock purchase agreements, so total shares outstanding did not change. Those agreements allow repurchases of up to 1,833,344 shares in private transactions using proceeds from future offerings.

Because the selling stockholders no longer hold a majority of voting power, Guardian ceased to qualify as a NYSE “controlled company” and will comply with full NYSE governance requirements. Effective March 20, 2026, the board formed a Nominating and Governance Committee composed entirely of independent directors.

Guardian Pharmacy Services, Inc. is registering 6,000,000 shares of Class A common stock, consisting of 1,020,000 newly issued shares and 4,980,000 shares offered by the Guardian Founders in a mixed primary and resale offering.

The Company will receive net proceeds of approximately $30.3 million from the 1,020,000 primary shares, which it intends to use to purchase 1,020,000 outstanding Class A shares in a "Synthetic Secondary" at the public offering price less the underwriting discount; after that repurchase the Company does not expect to have remaining net proceeds. The selling stockholders will receive proceeds from their 4,980,000-share resale and the Company will not receive proceeds from those shares. The Guardian Founders’ sales will cause the Company to cease qualifying as a NYSE "controlled company."

Guardian Pharmacy Services, Inc. is registering 5,000,000 shares of Class A common stock in a shelf prospectus supplement dated March 18, 2026. The company is offering 1,020,000 shares and the Guardian Founders are offering 3,980,000 shares.

The company will receive estimated net proceeds of approximately $34.8 million from its 1,020,000-share sale, which it intends to use to purchase 1,020,000 outstanding Class A shares in a “Synthetic Secondary” at the public offering price less underwriting discounts, leaving no remaining net proceeds. The selling stockholders’ sales will not provide proceeds to the company. Guardian’s Class A common stock last traded at $34.09 on the NYSE on March 17, 2026.

Guardian Pharmacy Services, Inc. describes its long-term care pharmacy business in this annual report. The company runs 61 pharmacies, including 54 full-service sites, serving about 205,000 residents in roughly 8,400 facilities across 38 states, with a particular focus on assisted living and behavioral health facilities.

More than two-thirds of revenue comes from these target settings, and about 71% of 2025 revenue was paid through Medicare Part D. Guardian highlights its high-touch service model, extensive automation, proprietary data platforms (Guardian Compass and GuardianShield), and a reported 89% resident adoption rate in assisted living communities it serves.